Stavropoulos, Nikolaos https://orcid.org/0009-0001-4093-1200
Myszkowski, Daniel
Braß, Dennis
Dervenis, Vasileios
Poungoura, Effimia
Stockfleth, Eggert
Funding for this research was provided by:
Almirall
Article History
Received: 28 October 2025
Accepted: 8 December 2025
First Online: 12 January 2026
Declarations
:
: Nikolaos Stavropoulos has received honoraria for participation in advisory boards, in clinical trials, support for conferences and meetings and/or as a speaker from LEO Pharma, Galderma, Almirall, Johnson&Johnson, Pfizer, Abbvie, and Astra Zeneca. Eggert Stockfleth has received lecture fees from Almirall, Leo, Pierre Favre and Philips. Vasileios Dervenis has received honoraria as a speaker for Abbvie, Almirall, Leo Pharma and support for conferences and meetings by Almirall, Pfizer, Johnson&Johnson, Galderma. Dennis Braß and Effimia Poungoura have received support for conferences and meetings by Pfizer, Johnson&Johnson, Almirall and Galderma. Daniel Myszkowski declares no conflict of interest.
: The study was conducted in accordance with the ethical principles of the Declaration of Helsinki [ ] and approved by the Westfalen-Lippe Ethics Committee (reference 2025–563-f-S). Because of the retrospective nature of the study, the requirement for informed consent was waived.